

# The Evolving Landscape of Psoriatic Arthritis: Why Early Diagnosis and Treatment Matter More Than Ever

Jasmin Khanum\*

Department of Medicine, Al-Jazzera University, Syria

\*Author for Correspondence:  
jasmin67@yahoo.com

Received: 02-Sep-2024, Manuscript No. fmijcr-24-156548; Editor assigned: 04-Sep-2024, Pre-QC No. fmijcr-24-156548 (PQ); Reviewed: 17-Sep-2024, QC No. fmijcr-24-156548; Revised: 23-Sep-2024, Manuscript No. fmijcr-24-156548 (R); Published: 30-Sep-2024, DOI: 10.37532/1758-4272.2024.19(9).233-236

## Introduction

Psoriatic arthritis (PsA) is a chronic, inflammatory disease that not only affects the skin but also targets the joints, entheses (where tendons and ligaments attach to bones), and the spine. It is part of the broader spectrum of autoimmune diseases, often emerging in patients with psoriasis, though it can also develop independently. Over the past few decades, significant strides have been made in understanding PsA, particularly in the areas of early diagnosis and treatment. Despite these advances, many individuals with PsA continue to experience delayed diagnoses, which can lead to irreversible joint damage, disability, and decreased quality of life. As the disease landscape continues to evolve, there is an urgent need to emphasize the importance of early recognition and intervention in PsA, which could substantially alter the course of the disease and improve long-term outcomes [1-5].

## The Burden of Psoriatic Arthritis

PsA affects approximately 30% of people with psoriasis, with an estimated global prevalence of 0.1–0.3%. The condition can vary widely in its severity and manifestation. While some individuals experience only mild joint pain and stiffness, others may develop severe arthritis that leads to significant deformity and functional impairment. The disease affects multiple joints, including the hands, knees, hips, and spine, and in more severe cases, it can lead to permanent joint damage. PsA can also involve other systems, including the eyes, heart, and gastrointestinal tract, further

complicating treatment [6].

One of the most challenging aspects of PsA is its unpredictable course. Joint symptoms may fluctuate, sometimes with periods of relative quietness followed by flare-ups. However, even in the absence of visible symptoms, the underlying inflammation may be causing damage to the joints and tissues. Over time, untreated or poorly controlled PsA can lead to irreversible joint destruction and disability, underscoring the importance of early intervention.

## Why Early Diagnosis Matters

The key to managing PsA effectively is early diagnosis. While PsA can be difficult to distinguish from other forms of arthritis, especially early on, there are several red flags that should raise suspicion, particularly in patients with psoriasis. These include:

- Joint pain and stiffness in the hands, feet, or lower back.
- Dactylitis (sausage-shaped swelling of fingers or toes).
- Sacroiliitis, or inflammation of the sacroiliac joints, which can lead to lower back pain.
- Enthesitis, the inflammation at tendon and ligament insertion points, which can cause pain in areas like the Achilles tendon, elbows, and knees.

Despite these warning signs, many people with PsA are not diagnosed until the disease has already caused significant joint damage. This delay in diagnosis is a major problem, as

it gives the disease time to progress unchecked. Research has shown that the sooner PsA is diagnosed and treated, the better the long-term outcomes. Early treatment can prevent permanent joint damage, reduce the severity of symptoms, and improve the patient's quality of life.

The challenge in diagnosing PsA is compounded by the fact that many patients may not initially associate their joint symptoms with their psoriasis, especially in the early stages. Additionally, PsA can present with a wide range of joint involvement, making it easy to misdiagnose as other forms of arthritis such as rheumatoid arthritis (RA) or osteoarthritis (OA). The key to distinguishing PsA from these conditions is recognizing the pattern of involvement (e.g., DIP joint involvement, dactylitis) and the patient's history of psoriasis or family history of autoimmune diseases [7-9].

#### Advancements in Diagnostic Tools

In recent years, there has been significant progress in diagnostic techniques that can aid in the early detection of PsA. These include:

- **Imaging:** Advances in imaging techniques, such as ultrasound and magnetic resonance imaging (MRI), have revolutionized the ability to detect early signs of PsA. These imaging modalities can reveal joint inflammation and soft tissue changes that may not yet be visible on X-rays, allowing clinicians to identify PsA before significant damage occurs. For example, MRI can detect sacroiliitis, a hallmark feature of axial PsA, even in the absence of overt symptoms.
- **Laboratory Biomarkers:** Although there are no specific blood tests for PsA, certain biomarkers are being explored to aid in diagnosis. Elevated levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are common in active disease and can be useful in monitoring inflammation. Additionally, research is underway to identify specific genetic and immunological markers that could improve early diagnosis and help predict disease progression.
- **Clinical Criteria and Screening Tools:** The development of screening tools, such as the Psoriasis Epidemiology Screening Tool (PEST), has helped raise awareness among healthcare providers about the potential for PsA in patients with psoriasis. These tools can help identify individuals who may benefit from further evaluation by a rheumatologist.
- While these tools are invaluable in diagnosing PsA earlier, they are not perfect. Not all patients with early signs of the disease may meet the criteria for diagnosis, and some may be misclassified. This highlights the importance of clinical expertise and suspicion in

making the diagnosis.

#### Why Early Treatment is Crucial

Once PsA is diagnosed, initiating treatment as early as possible is critical to managing the disease effectively. Early intervention can not only prevent joint damage but also reduce the long-term disability and improve the overall prognosis. The primary goal of treatment is to control inflammation, prevent joint destruction, and improve function and quality of life.

- **Nonsteroidal anti-inflammatory drugs (NSAIDs):** While NSAIDs can help manage symptoms by reducing inflammation, they do not alter the course of the disease. They are useful for mild cases or as adjuncts to other therapies.
- **Disease-Modifying anti-Rheumatic drugs (DMARDs):** Traditional DMARDs, such as methotrexate, leflunomide, and sulfasalazine, are often used to treat peripheral arthritis. However, these medications take time to work and may not be effective for everyone. Methotrexate remains the most commonly used DMARD for PsA, particularly for patients with predominantly peripheral disease.
- **Biologic therapies:** The advent of biologics has been a game-changer for PsA treatment. Tumor necrosis factor (TNF) inhibitors, such as etanercept, infliximab, and adalimumab, as well as newer agents targeting interleukin-12/23 and interleukin-17 (IL-17) pathways, have shown remarkable efficacy in controlling both skin and joint manifestations of PsA. Biologics are often reserved for patients with moderate-to-severe disease or those who do not respond to conventional DMARDs. They can dramatically reduce symptoms, prevent joint damage, and improve quality of life [10].
- **Janus kinase (JAK) inhibitors:** These newer oral medications, such as tofacitinib, have shown promise in treating PsA by targeting specific pathways involved in inflammation. JAK inhibitors may offer an alternative to biologics, especially for patients who cannot tolerate or have contraindications to injectable therapies.

The key to successful treatment is early and aggressive intervention to control inflammation before it causes irreversible damage. Long-term studies have shown that achieving early remission or low disease activity is associated with better functional outcomes, less joint damage, and a more favorable overall prognosis.

#### The Role of Multidisciplinary Care

Managing PsA requires a multidisciplinary approach. Rheumatologists, dermatologists, physical therapists, and primary care providers all play crucial roles in

delivering comprehensive care. Rheumatologists are primarily responsible for managing the joint and systemic aspects of the disease, while dermatologists address the skin manifestations. Early referral to a rheumatologist is essential for patients with suspected PsA, particularly those with moderate or severe disease. Physical therapy can help maintain joint function and mobility, especially in patients with axial involvement, while primary care providers can help manage comorbidities such as cardiovascular disease and diabetes, which are more prevalent in people with PsA.

### **Conclusion**

Psoriatic arthritis is a complex, progressive disease that

can cause irreversible joint damage if left untreated. Early diagnosis and intervention are key to preventing long-term disability and improving patient outcomes. While advancements in diagnostic tools and treatments have improved the outlook for PsA patients, there is still much work to be done. Raising awareness among healthcare providers and patients, improving access to early diagnostic services, and ensuring timely treatment are essential to optimizing care. In the evolving landscape of PsA, early action truly makes a difference, offering patients the best chance for a better quality of life and a future free from debilitating joint damage.

**References**

1. Yehuda Z, Alper A, Scott D, *et al.* Aneurysmal bone cyst of mandibular condyle: A case report and review of the literature. *J Craniomaxillofac Surg.* 40, 243-248 (2012).
2. Mankin HJ, Hornicek FJ, Ortiz-Cruz E, *et al.* Aneurysmal bone cyst: a review of 150 patients. *J Clin Oncol.* 23, 6756-6762 (2005).
3. Baig R, Eady J. Unicameral (simple) bone cysts. *Southern Med J.* 99, 966-976 (2006).
4. Rapp TB, Ward JP, Alaia MJ. Aneurysmal Bone Cyst. *J Am Acad Orthop Surg.* 20, 233-241 (2012).
5. Rodrigues CD, Carlos E. Traumatic Bone Cyst Suggestive of Large Apical Periodontitis. *J Endod.* 34, 484-489 (2008).
6. Kayani B, Sharma A, Sewell MD, *et al.* A Review of the Surgical Management of Extrathoracic Solitary Fibrous Tumors. *Am J Clin Oncol.* 41, 687-694 (2018).
7. Choi H, Charnsangavej C, Faria SC. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. *J Clin Oncol.* 25, 1753-1759 (2007).
8. Taniguchi S, Ryu J, Seki M. Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. *J Orthop Res.* 30, 673-678 (2012).
9. Reginster J-Y, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. *Rheumatology.* 46, 731-735 (2007).
10. Scholtissen S, Bruyère O, Neuprez A, *et al.* Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. *Int J Clin Pract.* 64, 756-762 (2010).